Rifapentine daily + Rifapentine weekly

ApprovedWithdrawn

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Tuberculosis

Conditions

Tuberculosis, Hiv

Trial Timeline

May 1, 2021 → Nov 1, 2021

NCT ID

NCT04551573

About Rifapentine daily + Rifapentine weekly

Rifapentine daily + Rifapentine weekly is a approved stage product being developed by Gilead Sciences for Tuberculosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04551573. Target conditions include Tuberculosis, Hiv.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04551573	Approved	Withdrawn	May 1, 2021	Nov 1, 2021	Tuberculosis

Competing Products

20 competing products in Tuberculosis

See all competitors

Product	Company	Stage	Hype Score
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
BCG Vaccine USP + Isoniazid + Rifampin	Merck	Phase 1	33
MK-7762 (TBD09)	Merck	Phase 1	33
Doravirine (DOR) + Rifapentine (RPT) + Isoniazid (INH)	Merck	Phase 1	33
Indacaterol + Control	Novartis	Phase 3	77
Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1 + Ag85B-ESAT6 fusion protein H1	Novartis	Phase 1	33
Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid	Novartis	Phase 2	52
Rifampicin + Isoniazid + Pyrazinamide + Kanamycin + Moxifloxacin	Novartis	Phase 1	33
rifabutin	Pfizer	Pre-clinical	22
Linezolid + Ethambutol	Pfizer	Phase 2	51
Myrin© 2 (Rifampicin + Isoniazid) + Rimactane® (Rifampicin)	Pfizer	Phase 1	32
Azacitidine Injection	Bristol Myers Squibb	Phase 1/2	40
Rifapentine + Isoniazid	Sanofi	Phase 1/2	40
AERAS-404 + Placebo + Bacillus Calmette-Guérin (BCG)	Sanofi	Phase 2	51
rifampin + rifapentine + rifapentine + rifapentine	Sanofi	Phase 2	51
rifapentine (M000473) + EFZ EMT TDF	Sanofi	Phase 1	32
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin	Sanofi	Phase 3	76
Rifampicin in higher doses	Sanofi	Phase 2	51
Higher-Dose Rifampin	Sanofi	Phase 2	51
Rifampin & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine & midazolam + rifapentine and midazolam + rifapentine and midazolam	Sanofi	Phase 1	32

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved